Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.58T | 4.26T | 4.03T | 3.57T | 3.20T |
Gross Profit | 2.36T | 2.83T | 2.78T | 2.46T | 2.20T |
EBITDA | 1.15T | 874.60B | 1.18T | 1.18T | 983.72B |
Net Income | 107.93B | 144.07B | 317.02B | 230.06B | 376.00B |
Balance Sheet | |||||
Total Assets | 14.25T | 15.11T | 13.96T | 13.18T | 12.91T |
Cash, Cash Equivalents and Short-Term Investments | 385.11B | 457.80B | 553.70B | 875.00B | 1.00T |
Total Debt | 4.52T | 4.84T | 4.38T | 4.35T | 4.64T |
Total Liabilities | 7.31T | 7.83T | 7.60T | 7.49T | 7.74T |
Stockholders Equity | 6.94T | 7.27T | 6.35T | 5.68T | 5.17T |
Cash Flow | |||||
Free Cash Flow | 761.70B | 235.61B | 343.47B | 937.07B | 774.46B |
Operating Cash Flow | 962.49B | 716.34B | 977.16B | 1.12T | 1.01T |
Investing Cash Flow | -385.36B | -463.86B | -607.10B | -198.13B | 393.53B |
Financing Cash Flow | -638.44B | -354.42B | -709.15B | -1.07T | -1.09T |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $6.89T | 63.64 | 1.50% | 4.53% | 7.45% | -25.77% | |
52 Neutral | $7.61B | 0.11 | -63.03% | 2.07% | 16.35% | 0.29% | |
― | $3.08B | 21.04 | 13.50% | ― | ― | ― | |
― | $7.98B | 23.82 | 5.34% | 0.15% | ― | ― | |
― | $1.97B | 15.48 | 7.24% | 2.14% | ― | ― | |
― | $15.15B | 12.33 | 12.99% | 0.16% | ― | ― | |
― | $1.90B | 8.92 | 11.16% | 0.14% | ― | ― |
Takeda Pharmaceutical Co announced positive results from two pivotal Phase 3 studies of oveporexton (TAK-861) in treating narcolepsy type 1. The studies met all primary and secondary endpoints, demonstrating statistically significant improvements across symptoms and reinforcing the potential of oveporexton to transform the standard of care. The drug was generally well-tolerated, and Takeda is advancing regulatory submissions to bring oveporexton to market quickly. This development marks a significant advancement in addressing the underlying cause of narcolepsy type 1 and positions Takeda for future growth in the orexin biology field.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co. has completed the disposal of treasury shares under its Long-Term Incentive Plan for employees outside Japan, with a slight reduction in the number of shares due to partial forfeiture of rights by some allottees. This change is expected to have an immaterial impact on the company’s full-year financials, indicating a stable operational outlook despite the adjustment.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co announced new assignments of directors following its 149th Annual Meeting of Shareholders. The board, comprised predominantly of external directors, underscores Takeda’s commitment to strong, independent governance. This governance model is crucial for aligning decisions with stakeholder interests and maintaining the company’s values. The new assignments include roles in the Nomination and Compensation Committees, further emphasizing the company’s focus on transparency and objectivity in its operations.
The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4200.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co announced the disposal of 17,355,770 treasury shares under its Long-Term Incentive Plan (LTIP) for employees outside Japan, valued at 75.25 billion yen. This initiative aims to align employee interests with shareholders, attract and retain talent, and balance risk and reward, potentially enhancing the company’s competitive positioning and operational efficiency.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Co. announced its plan to withdraw a previous Shelf Registration Statement and file a new one in Japan to issue new shares or dispose of treasury shares. This move is aimed at supporting the company’s Long Term Incentive Plan (LTIP) for employees. The scheduled issue amount is up to JPY 220 billion, with an expected share dilution of around 1.1% for the fiscal year ending March 31, 2026. This strategic decision allows Takeda to manage its equity more flexibly and aligns with its ongoing efforts to incentivize its workforce.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda and Protagonist Therapeutics announced the full 32-week results of their Phase 3 VERIFY study on rusfertide, presented at the ASCO Annual Meeting. The study, which targeted patients with polycythemia vera, successfully met its primary and secondary endpoints, demonstrating significant reductions in phlebotomy and improved hematocrit control. Despite the positive clinical outcomes, the impact on Takeda’s financial results for FY2025 is expected to be minimal.
The most recent analyst rating on (JP:4502) stock is a Buy with a Yen5500.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.
Takeda Pharmaceutical Company has announced the continuation of its stock compensation plans for directors and management in Japan, initially introduced in 2014 and 2016. These plans aim to align the interests of directors with shareholders by linking compensation to company performance, thereby enhancing corporate value and ensuring effective supervisory functions.
Takeda Pharmaceutical Company reported its consolidated financial results for the fiscal year ended March 31, 2025, showing a 7.5% increase in revenue to 4,581,551 million JPY. Despite the revenue growth, the company experienced a 25% decline in net profit attributable to owners, amounting to 107,928 million JPY. The company’s financial position reflects a decrease in total assets and equity, while cash flow from operating activities improved significantly. The company has also announced a dividend increase and provided forecasts for the next fiscal year, indicating a slight revenue decline but a substantial increase in operating profit and net profit.